Vycor Medical swings to Q1 FY26 profit of $20,108; revenue rises 5% to $458,540

VYCOR MEDICAL INC

VYCOR MEDICAL INC

VYCO

0.00
  • Vycor Medical posted net income of USD 20,108 for the three months ended March 31, 2026, swinging from a loss a year earlier.
  • Revenue rose 5% to USD 458,540, led by Vycor Medical segment sales up 5% to USD 440,441.
  • Selling, general and administrative expense fell 10.08% to USD 315,365, while research and development expense was USD 0.
  • Cash climbed to USD 173,634 at March 31, 2026, while working capital deficit widened to USD 4.3 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023615), on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.